| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
Departments of Surgery [R. D. G., S. L. S., D. C. C., M. P. L.] and Cell Biology [R. A. R., P. A. M., V. M. R.], Sloan-Kettering Institute and Memorial Sloan-Kettering Cancer Center, New York, New York 10021
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Several interesting observations have been made in high-risk neuroblastoma tumors. First, conventional multiagent chemotherapy often results in dramatic reductions in tumor mass after initial treatment, suggesting a strong primary apoptotic response (3) . Second, histopathology reveals that, in many cases, neuroblastoma tumors are composed of both pathogenic undifferentiated neuroblasts and neuronal lineage cells at various stages of differentiation. In addition, other neural crest cell types, such as melanocytes and glial cells, may be detected in these tumors (4) . These observations suggest that neuroblastoma tumors, even those considered high risk, retain the biochemical pathways mediating both programmed cell death (apoptosis), as well as multilineage terminal differentiation (5, 6, 7) .
Many children die of recurrent disease despite intensive chemotherapeutic regimens and, to date, cytodifferentiation therapies have proven disappointing (8) . For these reasons, new and different classes of agents are being investigated in neuroblastoma to improve outcome.
Most studies of neuroblastoma involve analyses of tumor-derived cell lines. Many neuroblastoma cell lines have a mixed population of tumor-derived cell types that have been subcloned into three identifiable morphological groups (9 , 10) . Of these, the neuritic or N-type neuroblastoma cell is the most relevant to neuroblastoma disease. N-type cells express several markers and chromosomal abnormalities frequently found in undifferentiated neuroblastoma tumor isolates (1) and have retained the potential to form xenograft tumors in immunodeficient rodent models (11) . In addition, recent studies have demonstrated that, similar to undifferentiated neuroblastoma tumors, N-type neuroblastoma cell lines undergo apoptosis by CD95-dependent and CD95-independent mechanisms in response to a variety of cytotoxic drugs (12 , 13) . These cell lines have also been shown to terminally differentiate into sympathetic neurons and lose tumorigenic potential in response to a variety of cytodifferentiation agents (e.g., retinoic acid and its derivatives; Refs. 14, 15, 16, 17 ).
HDACs,4 enzymes that affect eukaryotic chromatin structure, have been shown recently to be a target for potent hydroxamic acid-based hybrid polar inducers of transformed cell differentiation (18) . In addition to chromatin remodeling, the HDAC enzyme complex has been linked with several important regulatory pathways for growth and differentiation. For example, HDAC is associated with the retinoblastoma protein pRB (19 , 20) and members of the c-myc family (21 , 22) . In addition, HDAC is the active mediator of the retinoid receptor repressor complex (23, 24, 25, 26) . Several compounds (e.g., butyrates) have been shown to inhibit HDAC activity with low potency, resulting in the accumulation of acetylated histones and an increase in transcriptionally active chromatin (27 , 28) . Butyrates have been shown to be relatively weak inducers of tumor cell apoptosis or differentiation (29, 30, 31, 32, 33, 34) . These compounds require relatively high concentrations (effective concentration in the millimolar range) and are known to influence other metabolic pathways (35, 36, 37, 38) . Thus, the links between the HDAC enzyme complex and the induction of apoptosis or differentiation remain unresolved.
The recent identification of more potent inhibitors of HDAC, such as TSA (39, 40, 41) , trapoxin (42) , and CBHA (18) , has fostered studies that suggest a role for the HDAC-associated complex in induced tumor cell differentiation or apoptosis. These inhibitors have been shown to induce differentiation in certain colonic tumors and leukemic cell lines (18 , 40 , 43 , 44) and promote apoptosis in T lymphocytes and other colonic tumor cell lines (45, 46, 47) . TSA was found to synergize with derivatives of retinoic acid to promote cellular differentiation of leukemias that exhibit retinoid resistance (24 , 25) . CBHA is a member of a recently synthesized family of hybrid polar compounds that have been shown to be inhibitors of HDAC (18) and potent inducers of transformed cell growth arrest and terminal differentiation at micromolar (4 µM) concentrations (48) . There has been a long-standing interest in cytodifferentiation therapy in neuroblastoma because of the ability to induce differentiation in vitro with multiple agents (10 , 14 , 15 , 17) . In addition, these tumors are found to contain cells in various states of differentiation in vivo (4) , and spontaneous maturation and involution of neuroblastoma has been documented (6) .
The present study was designed to investigate the effects of CBHA in neuroblastoma. We found that CBHA induced apoptosis in nine of nine cell lines investigated. It was observed that 0.5–4 µM CBHA induced dose-dependent decreases in cell viability and caspase-dependent apoptosis in all neuroblastoma cell lines investigated. Additional studies demonstrated that CBHA-induced apoptosis was inhibited by cycloheximide and that CBHA caused the rapid induction of the CD95/CD95-L system. These results suggest that CBHA and other members of these hydroxamic acid-based hybrid polar compounds are possible therapeutic agents in the treatment of neuroblastoma.
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Incubation with zVAD-fmk and Cycloheximide.
To inhibit caspase activity, neuroblastoma cells were preincubated with 60 µM zVAD-fmk (Calbiochem) for 3 h at 37°C before the addition of CBHA. Cells were preincubated with 0.5 µg/ml cycloheximide (Sigma Chemical Co.) for 1 h at 37°C before the addition of CBHA to assess the effect of inhibition of protein synthesis.
Flow Cytometry.
Cells were harvested by trypsinization, and cell suspensions were washed twice in PBS, then fixed in 80% ice-cold ethanol and stored at - 20°C until analysis. Before analysis, cell suspensions were digested by DNase-free RNase (Boehringer Mannheim) for 20 min at 37°C and then stained in a propidium iodide solution (50 µg/ml) containing 0.1% Triton X-100 overnight in the dark. Cell cycle analysis was performed with a FACScan equipped with a FACStation running CellQuest software (Becton Dickinson, San Jose, CA). Debris was eliminated from analysis using a forward angle light scatter threshold trigger. Cell doublets and other clumps were removed using analysis gates on either fluorescence pulse width or height versus pulse area (integral). Data for 1–2 x 106 single cells were collected/sample. Sub-G1 values were obtained by standard histogram analysis. Cell cycle analysis of DNA frequency histograms was performed with MultiCycle (Phoenix Flow System, San Diego, CA).
DNA Ladder Assay.
Cell cultures were established and treated with drug or solvent control. DNA for ladder assays was isolated as described previously (49)
. The resulting DNA samples were digested with 0.1 µg of RNase A at 37°C for 30 min before loading onto 1.2% agarose gels. The DNA was visualized by ethidium bromide staining.
Immunoblot Analysis.
Cells were trypsinized and washed in PBS without calcium and magnesium. Cell lysate buffer was prepared: 50 mM HEPES solution (pH 7.9), 250 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 0. 6% Triton X-100, and proteinase inhibitors. Lysate buffer was then added to the cells in the amount of 25 µl/million live cells. The mixture was then centrifuged at 16,000 x g for 1 min in sterile Eppendorf tubes. The supernatant was then mixed with an equal volume of sample buffer, which was prepared as: 20% glycerol, 0.125 M Tris (pH 6.8), 4% SDS, and both Pyronin Y and bromphenol blue (0.025% v/v) as tracking dyes. The preparations were then heated in a water bath to 90°C for 5 min and were stored at -80°C until used.
Protein extracts were thawed, and 30 µl were loaded/lane. They were separated on a 10% SDS-PAGE gel in a dual vertical slab gel electrophoresis cell (Bio-Rad). The protein was transferred to a nitrocellulose membrane (Micron Separations Inc.) for 2 h at 50 V in transfer buffer containing 3% Tris base, 14.4% glycine, and 20% methanol. The membrane was then stained for total protein with Ponceau-S (Sigma Chemical Co.) and blocked with 5% nonfat dry milk powder and 0.5% Tween 20 in PBS overnight. It was then washed three times with 0.5% Tween 20 in PBS for 15 min. The membrane was incubated with primary antibody [Fas or Fas-L (Santa Cruz Biotechnology)], diluted in 0.5% Tween 20/PBS for 1 h at room temperature, and then washed three times. Peroxidase-labeled secondary antibody (Jackson ImmunoResearch Laboratories) was then applied, and incubation was done for 30 min at room temperature, followed by 3 x 15 min washes. Enhanced chemiluminescence Western blotting detection system (Amersham) was applied for 1 min, and proteins were then visualized on Amersham Hyperfilm enhanced chemiluminescence film using exposure times varying from 30 s to 5 min.
Immunoblot Analysis of Isolated Histones.
Nuclei were isolated by lysis in buffer containing 10 mM Tris-HCl (pH 6.5), sodium bisulfite, 1% Triton X-100, 10 mM MgCl2, 8.6% sucrose, and Dounce homogenization. Histones were isolated by acid extraction, as described previously (18)
. Isolated histones (2.5 µg) were then separated on 15% SDS-PAGE minigels (Bio-Rad, Hercules, CA) and transferred to nitrocellulose (Schleicher and Schuell, Keene, NH). Hyperacetylated histones were detected by antibodies that specifically recognize the hyperacetylated form of histone H4 and histone H3 (Upstate Biotechnology) and were visualized by chemiluminescence (Pierce Chemical Co., Rockford, IL). As a control for the amount of protein loading, parallel gels were stained with Coomassie blue.
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
.
|
. The KCN-69n line yielded similar results (Fig. 2B)
. For the cell line SK-N-ER, this effect was seen only at concentrations >0.25 µ M (Fig. 2C)
. In the low-micromolar dose range (1–3 µM), there was a sharp decline in viable cell number for all three cell lines after 24 h of culture with CBHA. Culture of nine of nine human neuroblastoma cell lines [SK-N-BE(2)-M17, SK-N-BE(2)C, SK-N-SY5Y, SK-N-SH (EP1), BE(1)n, LA1-55n, LA1-5s, SMS-KCN (69n), and SK-N-ER] with CBHA lead to extensive cell death within 24–72 h. The LD50 in all nine cell lines ranged between 1 µM and 4 µM. Analysis of these results reveal that all neuroblastoma cell lines are sensitive to the effects of CBHA. Morphological examination of cultures 24–48 h after CBHA (1–2 µM) culture revealed extensive cellular debris with membrane blebbing and morphological appearances characteristic of apoptosis (data not shown).
|
revealed that only 12–24 h of culture with CBHA was necessary to reduce cell viability to the same level as observed with continuous 72-h exposure. This suggests that an irreversible process is initiated within 12–24 h of CBHA culture, which is sufficient to trigger its effects on neuroblastoma cell lines.
|
. Specific sub-G1 was calculated for each cell line and was found to increase up to 82% by 48 h of culture (Fig. 4B)
. The initial time course titration studies (Fig. 2)
demonstrated that CBHA in the nanomolar range resulted in reduced cell number by 72 h. This result suggested that the neuroblastoma cells were undergoing either growth inhibition or increased cell death as compared with controls. FACS analysis was performed on neuroblastoma cell lines treated with CBHA at concentrations below LD50 (0.25–1.0 µM) to determine whether there was an increase in the population of cells in the sub-G1 fraction. An example of this analysis is presented for the cell line SK-N-ER, where it was observed that there was a dose-dependent increase in the specific sub-G1 fraction (Fig. 4C)
. The FACS analysis also showed that there are no statistically significant changes in the G1-S-G2 phases of the cell cycle. These results confirm that CBHA induces cell death in neuroblastoma in a dose-dependent manner.
|
. The nucleic acid from untreated control cell lines had high molecular weight genomic DNA. The detection of substantial sub-G1 fractions combined with the presence of DNA ladders suggests that CBHA triggers an apoptotic pathway in the neuroblastoma cell lines. Apoptosis was also assessed by the TUNEL (terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling) staining method (50)
with fluorescent microscopic analysis and yielded results consistent with DNA fragmentation (data not shown).
|
. ZVAD-fmk alone had no detectable effect on cell growth or viability (data not shown). These results suggest that the cell death induced by CBHA is dependent on activation of the caspase cascade.
|
. For each cell line, control cultures and zVAD-fmk + CBHA-treated cultures underwent at least three to four cell divisions based on calculated doubling times (data not shown). This observation suggests that neuroblastoma cells continue to proliferate in the presence of both compounds. Furthermore, immunoblot analyses of extracts from control and CBHA-cultured cell lines revealed that there was no apparent change in the levels of expression of the cell cycle inhibitors p16INK4A, p21waf1, or p27kip1 (data not shown). These observations are consistent with CBHA causing an increase in cell death, even at low concentrations.
|
. These results suggest that CBHA activates an apoptotic pathway that is dependent on protein synthesis.
|
in three of three cell lines. CD95-L is an N-linked glycoprotein with a reported molecular weight of Mr 40,000 (52
, 53)
. The 40-kDa CD95-L polypeptide could be detected at low levels in two of three untreated cell lines (LA1-55n and SK-N-ER), whereas KCN-69n was observed to be negative for CD95-L expression (Fig. 9B)
. In addition, it was observed that CD95-L expression could be induced in all three cell lines within 12–24 h of CBHA culture. Other CD95-L species (molecular weight range, Mr 37,000–44,000) were observed in the immunoblots, and these may be due to variations in N-linked glycan density, as reported previously (54)
. Thus, both CD95 and CD95-L were induced in 12–24 h in all three cell lines. The temporal pattern of expression for these proteins is consistent with the results of the growth and flow cytometric analyses, where declines in cell viability and increases in the sub-G1 fraction were apparent 12–24 h after the addition of CBHA to the culture.
|
|
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
CBHA has been shown to inhibit HDACs (18) . In the present study, this agent was found to cause an accumulation of acetylated histone H3 and histone H4. Earlier studies showed that butyrate, an inhibitor of HDAC (28) , can induce apoptosis and/or differentiation of various solid tumor and hematopoietic cell types (29, 30, 31, 32, 33, 34 , 55 , 56) . Butyrate was reported to inhibit cell growth and induce differentiation in two human neuroblastoma cell lines (57 , 58) , and induction of programmed cell death was observed in another at millimolar concentrations of butyrate (37) . At these relatively high concentrations, it has been suggested that butyrate may alter other cellular machinery, in addition to inhibiting HDAC (35, 36, 37, 38) . The half-life of this fatty acid in vivo is very short and has limited its effectiveness as a therapeutic agent (59, 60, 61) . We have shown that CBHA induces an apoptotic effect in all nine human neuroblastoma cell lines investigated at micromolar concentrations (LD50 range, 1–4 µM). Moreover, dose-dependent increases in apoptosis were detected in cell lines cultured with CBHA in the nanomolar range. This range of effective concentrations is consistent with previous studies in which CBHA was shown to induce terminal differentiation in MEL cells (48) . Furthermore, the present data show that brief exposure to CBHA (4 h) leads to the accumulation of acetylated histones, which was also demonstrated in MEL cells (18) .
Our data also reveal that the irreversible commitment to programmed cell death was achieved within 12–24 h of drug exposure, consistent with the activation of a proapoptotic cascade. The caspase enzymes are considered key effector molecules thought to be required for most apoptotic pathways (51) . In human neuroblastoma cells, they have been shown to be necessary for the cytotoxic effects of anticancer agents (62) . Our data indicate that inhibition of caspase activity leads to abrogation of CBHA-induced apoptosis.
Recently, Fulda et al. (13 , 62) demonstrated the importance of the CD95/CD95-L system in the apoptotic response to chemotherapeutic agents, such as doxorubicin, cisplatinum, and VP-16, in neuroblastoma cells. In those studies, both CD95 and CD95-L induction preceded caspase-dependent apoptosis (13) . Similarly, we have shown that CBHA induces CD95 and CD95-L in neuroblastoma cells and observed that the time course of induction of apoptosis parallels that of induction of CD95.
Indeed, the chemotherapeutic agents described above all have been used clinically in the treatment of neuroblastoma. They are distinct from each other in their known mechanisms of intracellular activity, but all have been shown to induce apoptosis via the CD95/CD95-L system. This observation emphasizes the importance of CD95-dependent apoptotic induction in the treatment of neuroblastoma. Several pathways (including the generation of ceramide, activation of the c-jun NH2-terminal kinase/stress-activated protein kinase-dependent stress pathway, and the accumulation of p53) have been implicated in the induction of the CD95 system, leading to apoptosis (63, 64, 65, 66) . The mechanism regulating the increased expression of these proteins by CBHA in neuroblastoma is an intriguing question to be explored. It would be useful to have multiple modalities by which to induce and maintain CD95 sensitivity in tumors. HDAC inhibition may affect the expression of these genes by chromatin alteration and transcriptional activation (67) . Alternatively, HDAC inhibition may induce other intracellular pathways that then activate the death receptor pathway.
The multidrug resistance gene, MDR, and the multidrug resistance-associated protein, MRP, have been implicated in chemoresistance and poor outcome in neuroblastoma (68 , 69) . The drug efflux mechanism is associated with many of the agents used in the treatment of this disease, including the drugs discussed above. In previous studies, MDR positive, vincristine-resistant MEL cells were shown to be sensitive to the effects of CBHA (48) . Preliminary studies in our laboratory with the vincristine-resistant neuroblastoma cell line BE(2)C-VCR suggest that these cells are susceptible to CBHA.5 The investigation of this agent in the context of MDR-amplified neuroblastoma cell lines will be important.
Combination therapies with HDAC inhibitors and retinoids have recently become an area of keen interest and investigation. In vitro studies have shown neuroblastoma cell lines to be responsive to the effects of retinoic acid (14 , 15) , yet retinoid therapies in patients have proven discouraging (8) . Recent work has shown that in the absence of retinoic acid ligand, the RAR and RXR nuclear retinoic acid receptor families are associated with a protein repressor complex, which includes SMRT/mSin3 and HDAC (26) . Indeed, several recent studies demonstrated that the addition of HDAC inhibitors enhances retinoic acid-induced differentiation in leukemic model systems (23, 24, 25, 26) . There is a recent study of a patient with recurrent retinoid-resistant acute promyelocytic leukemia who achieved complete clinical and cytogenetic remission after the addition of a HDAC inhibitor to all-trans-retinoic-acid therapy (70) . Current investigation in our laboratory suggests that CBHA can enhance retinoid sensitivity in neuroblastoma cell lines, and we have initiated studies of CBHA and the drug combination on tumor xenografts.6
Our results suggest that CBHA and other potent HDAC inhibitors may have therapeutic potential in the treatment of neuroblastoma.
|
FOOTNOTES |
|---|
1 Supported in part by a grant from the I. W. Foundation. 
2 These authors contributed equally to this work.
3 To whom requests for reprints should be addressed, at Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021. Phone: (212) 639-7002; Fax: (212) 717-3373; E-mail: laquaglm{at}mskcc.org
4 The abbreviations used are: HDAC, histone deacetylase; CBHA, M-carboxycinnamic acid bishydroxamide; TSA, trichostatin A; CD95-L, CD95 ligand; zVAD-fmk, benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone; FACS, fluorescence activated cell sorting; MEL, murine erythroleukemia.
5 S. Swendeman, unpublished observation.
6 D. Coffey, S. Swendeman, R. Glick, V. M. Richon, and M. P. La Quaglia. Analysis of the effects of histone deacetylase inhibitors and retinoic acid on the growth of neuroblastoma in vitro and in vivo, manuscript in preparation.
Received 3/ 8/99. Accepted 7/ 7/99.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
, retinoic acid and dibutyryl cyclic AMP. Int. J. Cancer, 39: 521-529, 1987.[Medline]
recruit histone deacetylase in promyelocytic leukemia. Nature (Lond.), 391: 815-818, 1998.[Medline]
and PLZF-RAR with co-repressors determine differential responses to RA in APL. Nat. Genet., 18: 126-135, 1998.[Medline]
phosphorylation and programmed cell death in human neuroblastoma cells. Brain Res., 688: 86-94, 1995.[Medline]
2A-adrenergic receptor expression in the human colon carcinoma cell line HT29: SCFA-induced enterocytic differentiation results in an inhibition of 2C10 gene transcription. Proc. Assoc. Am. Physicians, 108: 334-344, 1996.[Medline]
This article has been cited by other articles:
|
|
 |
|
  M. M.H.J. van Gelder, I. A.L.M. van Rooij, R. K. Miller, G. A. Zielhuis, L. T.W. de Jong-van den Berg, and N. Roeleveld Teratogenic mechanisms of medical drugs Hum. Reprod. Update, January 7, 2010; (2010) dmp052v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Inoue, N. Harper, R. Walewska, M. J.S. Dyer, and G. M. Cohen Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis Mol. Cancer Ther., November 1, 2009; 8(11): 3088 - 3097. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. K. Hahn, K. N. Ross, I. M. Warrington, R. Mazitschek, C. M. Kanegai, R. D. Wright, A. L. Kung, T. R. Golub, and K. Stegmaier Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation PNAS, July 15, 2008; 105(28): 9751 - 9756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Garcia-Manero, H. Yang, C. Bueso-Ramos, A. Ferrajoli, J. Cortes, W. G. Wierda, S. Faderl, C. Koller, G. Morris, G. Rosner, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes Blood, February 1, 2008; 111(3): 1060 - 1066. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. R. Fantin and V. M. Richon Mechanisms of Resistance to Histone Deacetylase Inhibitors and Their Therapeutic Implications Clin. Cancer Res., December 15, 2007; 13(24): 7237 - 7242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Gillenwater, M. Zhong, and R. Lotan Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells Mol. Cancer Ther., November 1, 2007; 6(11): 2967 - 2975. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Ikegaki, T. Gotoh, B. Kung, J. S. Riceberg, D. Y. Kim, H. Zhao, E. F. Rappaport, S. L. Hicks, R. C. Seeger, and X. X. Tang De novo Identification of MIZ-1 (ZBTB17) Encoding a MYC-Interacting Zinc-Finger Protein as a New Favorable Neuroblastoma Gene Clin. Cancer Res., October 15, 2007; 13(20): 6001 - 6009. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. De los Santos, A. Zambrano, and A. Aranda Combined effects of retinoic acid and histone deacetylase inhibitors on human neuroblastoma SH-SY5Y cells Mol. Cancer Ther., April 1, 2007; 6(4): 1425 - 1432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. H. Rubin, N. G.B. Agrawal, E. J. Friedman, P. Scott, K. E. Mazina, L. Sun, L. Du, J. L. Ricker, S. R. Frankel, K. M. Gottesdiener, et al. A Study to Determine the Effects of Food and Multiple Dosing on the Pharmacokinetics of Vorinostat Given Orally to Patients with Advanced Cancer Clin. Cancer Res., December 1, 2006; 12(23): 7039 - 7045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Inoue, A. Mai, M. J.S. Dyer, and G. M. Cohen Inhibition of Histone Deacetylase Class I but not Class II Is Critical for the Sensitization of Leukemic Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis. Cancer Res., July 1, 2006; 66(13): 6785 - 6792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Graham, C. Tucker, J. Creech, E. Favours, C. A. Billups, T. Liu, M. Fouladi, B. B. Freeman III, C. F. Stewart, and P. J. Houghton Evaluation of the Antitumor Efficacy, Pharmacokinetics, and Pharmacodynamics of the Histone Deacetylase Inhibitor Depsipeptide in Childhood Cancer Models In vivo Clin. Cancer Res., January 1, 2006; 12(1): 223 - 234. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Garcia-Morales, A. Gomez-Martinez, A. Carrato, I. Martinez-Lacaci, V. M. Barbera, J. L. Soto, E. Carrasco-Garcia, M. P. Menendez-Gutierrez, M. D. Castro-Galache, J. A. Ferragut, et al. Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines Mol. Cancer Ther., August 1, 2005; 4(8): 1222 - 1230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. C. Ryan, D. Headlee, M. Acharya, A. Sparreboom, J. B. Trepel, J. Ye, W. D. Figg, K. Hwang, E. J. Chung, A. Murgo, et al. Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or Lymphoma J. Clin. Oncol., June 10, 2005; 23(17): 3912 - 3922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. N. Bhalla Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies J. Clin. Oncol., June 10, 2005; 23(17): 3971 - 3993. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Mitsiades, V. Poulaki, C. McMullan, J. Negri, G. Fanourakis, A. Goudopoulou, V. M. Richon, P. A. Marks, and N. Mitsiades Novel Histone Deacetylase Inhibitors in the Treatment of Thyroid Cancer Clin. Cancer Res., May 15, 2005; 11(10): 3958 - 3965. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. W. Laird Cancer epigenetics Hum. Mol. Genet., April 15, 2005; 14(suppl_1): R65 - R76. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Peart, G. K. Smyth, R. K. van Laar, D. D. Bowtell, V. M. Richon, P. A. Marks, A. J. Holloway, and R. W. Johnstone Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors PNAS, March 8, 2005; 102(10): 3697 - 3702. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Adachi, Y. Zhang, X. Zhao, T. Minami, R. Kawamura, Y. Hinoda, and K. Imai Synergistic Effect of Histone Deacetylase Inhibitors FK228 and m-Carboxycinnamic Acid Bis-Hydroxamide with Proteasome Inhibitors PSI and PS-341 against Gastrointestinal Adenocarcinoma Cells Clin. Cancer Res., June 1, 2004; 10(11): 3853 - 3862. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Guo, C. Sigua, J. Tao, P. Bali, P. George, Y. Li, S. Wittmann, L. Moscinski, P. Atadja, and K. Bhalla Cotreatment with Histone Deacetylase Inhibitor LAQ824 Enhances Apo-2L/Tumor Necrosis Factor-Related Apoptosis Inducing Ligand-Induced Death Inducing Signaling Complex Activity and Apoptosis of Human Acute Leukemia Cells Cancer Res., April 1, 2004; 64(7): 2580 - 2589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Atadja, L. Gao, P. Kwon, N. Trogani, H. Walker, M. Hsu, L. Yeleswarapu, N. Chandramouli, L. Perez, R. Versace, et al. Selective Growth Inhibition of Tumor Cells by a Novel Histone Deacetylase Inhibitor, NVP-LAQ824 Cancer Res., January 15, 2004; 64(2): 689 - 695. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Duan, Z. Zhou, S.-F. Jia, M. Colvin, E. A. Lafleur, and E. S. Kleinerman Interleukin-12 Enhances the Sensitivity of Human Osteosarcoma Cells to 4-Hydroperoxycyclophosphamide by a Mechanism Involving the Fas/Fas-Ligand Pathway Clin. Cancer Res., January 15, 2004; 10(2): 777 - 783. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Mitsiades, N. S. Mitsiades, C. J. McMullan, V. Poulaki, R. Shringarpure, T. Hideshima, M. Akiyama, D. Chauhan, N. Munshi, X. Gu, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications PNAS, January 13, 2004; 101(2): 540 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Kutko, R. D. Glick, L. M. Butler, D. C. Coffey, R. A. Rifkind, P. A. Marks, V. M. Richon, and M. P. LaQuaglia Histone Deacetylase Inhibitors Induce Growth Suppression and Cell Death in Human Rhabdomyosarcoma in Vitro Clin. Cancer Res., November 15, 2003; 9(15): 5749 - 5755. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Catley, E. Weisberg, Y.-T. Tai, P. Atadja, S. Remiszewski, T. Hideshima, N. Mitsiades, R. Shringarpure, R. LeBlanc, D. Chauhan, et al. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma Blood, October 1, 2003; 102(7): 2615 - 2622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Peart, K. M. Tainton, A. A. Ruefli, A. E. Dear, K. A. Sedelies, L. A. O'Reilly, N. J. Waterhouse, J. A. Trapani, and R. W. Johnstone Novel Mechanisms of Apoptosis Induced by Histone Deacetylase Inhibitors Cancer Res., August 1, 2003; 63(15): 4460 - 4471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Rosato, J. A. Almenara, and S. Grant The Histone Deacetylase Inhibitor MS-275 Promotes Differentiation or Apoptosis in Human Leukemia Cells through a Process Regulated by Generation of Reactive Oxygen Species and Induction of p21CIP1/WAF1 1 Cancer Res., July 1, 2003; 63(13): 3637 - 3645. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. D. Klisovic, S. E. Katz, D. Effron, M. I. Klisovic, J. Wickham, M. R. Parthun, M. Guimond, and G. Marcucci Depsipeptide (FR901228) Inhibits Proliferation and Induces Apoptosis in Primary and Metastatic Human Uveal Melanoma Cell Lines Invest. Ophthalmol. Vis. Sci., June 1, 2003; 44(6): 2390 - 2398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Mitsiades, C. S. Mitsiades, P. G. Richardson, C. McMullan, V. Poulaki, G. Fanourakis, R. Schlossman, D. Chauhan, N. C. Munshi, T. Hideshima, et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells Blood, May 15, 2003; 101(10): 4055 - 4062. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Kraker, C. A. Mizzen, B. G. Hartl, J. Miin, C. D. Allis, and R. L. Merriman Modulation of Histone Acetylation by [4-(Acetylamino)-N-(2-Amino-phenyl) Benzamide] in HCT-8 Colon Carcinoma Mol. Cancer Ther., April 1, 2003; 2(4): 401 - 408. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Wisniewski, C. L. Lambek, C. Liu, A. Strife, D. R. Veach, B. Nagar, M. A. Young, T. Schindler, W. G. Bornmann, J. R. Bertino, et al. Characterization of Potent Inhibitors of the Bcr-Abl and the c-Kit Receptor Tyrosine Kinases Cancer Res., August 1, 2002; 62(15): 4244 - 4255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. N. Munster, T. Troso-Sandoval, N. Rosen, R. Rifkind, P. A. Marks, and V. M. Richon The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Induces Differentiation of Human Breast Cancer Cells Cancer Res., December 1, 2001; 61(23): 8492 - 8497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-W. Han, S. H. Ahn, Y. K. Kim, G.-U. Bae, J. W. Yoon, S. Hong, H. Y. Lee, Y.-W. Lee, and H.-W. Lee Activation of p21WAF1/Cip1 Transcription through Sp1 Sites by Histone Deacetylase Inhibitor Apicidin. INVOLVEMENT OF PROTEIN KINASE C J. Biol. Chem., November 2, 2001; 276(45): 42084 - 42090. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Burgess, S. Pavey, R. Warrener, L.-J. K. Hunter, T. J. Piva, E. A. Musgrove, N. Saunders, P. G. Parsons, and B. G. Gabrielli Up-Regulation of p21WAF1/CIP1 by Histone Deacetylase Inhibitors Reduces Their Cytotoxicity Mol. Pharmacol., October 1, 2001; 60(4): 828 - 837. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Coffey, M. C. Kutko, R. D. Glick, L. M. Butler, G. Heller, R. A. Rifkind, P. A. Marks, V. M. Richon, and M. P. La Quaglia The Histone Deacetylase Inhibitor, CBHA, Inhibits Growth of Human Neuroblastoma Xenografts in Vivo, Alone and Synergistically with All-Trans Retinoic Acid Cancer Res., May 1, 2001; 61(9): 3591 - 3594. [Abstract] [Full Text]
|
|
|
|
|
|
L. M. Butler, Y. Webb, D. B. Agus, B. Higgins, T. R. Tolentino, M. C. Kutko, M. P. LaQuaglia, M. Drobnjak, C. Cordon-Cardo, H. I. Scher, et al. Inhibition of Transformed Cell Growth and Induction of Cellular Differentiation by Pyroxamide, an Inhibitor of Histone Deacetylase Clin. Cancer Res., April 1, 2001; 7(4): 962 - 970. [Abstract] [Full Text]
|
|
|
|
|
|
W.-G. Zhu, R. R. Lakshmanan, M. D. Beal, and G. A. Otterson DNA Methyltransferase Inhibition Enhances Apoptosis Induced by Histone Deacetylase Inhibitors Cancer Res., February 1, 2001; 61(4): 1327 - 1333. [Abstract] [Full Text]
|
|
|
|
 |
|
 W. J. Magner, A. L. Kazim, C. Stewart, M. A. Romano, G. Catalano, C. Grande, N. Keiser, F. Santaniello, and T. B. Tomasi Activation of MHC Class I, II, and CD40 Gene Expression by Histone Deacetylase Inhibitors J. Immunol., December 15, 2000; 165(12): 7017 - 7024. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Butler, D. B. Agus, H. I. Scher, B. Higgins, A. Rose, C. Cordon-Cardo, H. T. Thaler, R. A. Rifkind, P. A. Marks, and V. M. Richon Suberoylanilide Hydroxamic Acid, an Inhibitor of Histone Deacetylase, Suppresses the Growth of Prostate Cancer Cells in Vitro and in Vivo Cancer Res., September 1, 2000; 60(18): 5165 - 5170. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. A. Marks, V. M. Richon, and R. A. Rifkind Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells J Natl Cancer Inst, August 2, 2000; 92(15): 1210 - 1216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Kwon, S. H. Ahn, Y. K. Kim, G.-U. Bae, J. W. Yoon, S. Hong, H. Y. Lee, Y.-W. Lee, H.-W. Lee, and J.-W. Han Apicidin, a Histone Deacetylase Inhibitor, Induces Apoptosis and Fas/Fas Ligand Expression in Human Acute Promyelocytic Leukemia Cells J. Biol. Chem., January 11, 2002; 277(3): 2073 - 2080. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. M. Richon, T. W. Sandhoff, R. A. Rifkind, and P. A. Marks Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation PNAS, August 29, 2000; 97(18): 10014 - 10019. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Ruefli, M. J. Ausserlechner, D. Bernhard, V. R. Sutton, K. M. Tainton, R. Kofler, M. J. Smyth, and R. W. Johnstone The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species PNAS, September 11, 2001; 98(19): 10833 - 10838. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
), LA1-55n (
), and SK-N-ER (
). To assess the percentage of sub-G1 nuclei attributable to CBHA, the specific sub-G1 percentage was calculated as: [experimental sub-G1 (%) - spontaneous sub-G1 in medium (%)]/[100% - spontaneous sub-G1 in medium (%)] x 100 
